Last reviewed · How we verify

DTG/3TC/ABC + ELV/COBI/FTC/TAF — Competitive Intelligence Brief

DTG/3TC/ABC + ELV/COBI/FTC/TAF (DTG/3TC/ABC + ELV/COBI/FTC/TAF) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

DTG/3TC/ABC + ELV/COBI/FTC/TAF (DTG/3TC/ABC + ELV/COBI/FTC/TAF) — Fundacion SEIMC-GESIDA. This is a fixed-dose combination of two antiretroviral regimens that inhibit HIV reverse transcriptase and integrase to suppress viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DTG/3TC/ABC + ELV/COBI/FTC/TAF TARGET DTG/3TC/ABC + ELV/COBI/FTC/TAF Fundacion SEIMC-GESIDA marketed Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase
Raltegravir and Abacavir/Lamivudine Raltegravir and Abacavir/Lamivudine Denver Infectious Disease Consultants, PLLC marketed Antiretroviral combination (INSTI + NRTI) HIV integrase, HIV reverse transcriptase
DTG/ABC/3TC DTG/ABC/3TC Harvard School of Public Health (HSPH) marketed Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase
ELV/COBI/FTC/TAF ELV/COBI/FTC/TAF Fundacion SEIMC-GESIDA marketed Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster) HIV integrase, HIV reverse transcriptase
BIC/FTC/TAF BIC/FTC/TAF Prism Health North Texas marketed Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase
bictegravir/emtricitabine/tenofovir alafenamide bictegravir/emtricitabine/tenofovir alafenamide Midland Research Group, Inc. marketed Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase
Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill Charlotte-Paige Rolle, MD marketed Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) class)

  1. Fundacion SEIMC-GESIDA · 1 drug in this class
  2. Southampton Healthcare, Inc. · 1 drug in this class
  3. University of California, San Francisco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DTG/3TC/ABC + ELV/COBI/FTC/TAF — Competitive Intelligence Brief. https://druglandscape.com/ci/dtg-3tc-abc-elv-cobi-ftc-taf. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: